Inhibitor of Mitochondrial OXPHOS

ME-344, an inhibitor of mitochondrial OXPHOS, is a drug candidate with potential to treat solid tumors.

ME-344 is a novel drug candidate that in an inhibitor of mitochondrial oxidative phosphorylation (OXPHOS), a fundamental metabolic pathway involved in the production of adenosine triphosphate (ATP) in the mitochondria. Treatment of tumor cells with ME-344 as a single-agent results in a rapid loss of ATP and cancer cell death.

Although clinical investigation of ME-344 has demonstrated single agent activity in patients with solid tumors, using it in combination with other cancers therapies is thought to hold more significant potential for patients. Data reported from pre-clinical and clinical studies has demonstrated activity in combination anti-angiogenics, like the vascular endothelial growth factor (“VEGF”) inhibitor bevacizumab (AVASTIN®). ME-344 is continuing to advance via the ongoing development of a new formulation intended to improve biologic activity and patient convenience.

Additional Information

Mechanism of Action
Development Program
Patient Population:
Clinical Trials

Clinical Trials

MEI is actively recruiting patients to participate in clinical trials to evaluate our investigational cancer therapies.
View All
Patients & Caregivers

Patients & Caregivers

Our driving purpose and principle is simple: deliver novel and differentiated cancer therapies that provide improved outcomes for patients.
Learn More